Reverse Phase Protein Array (RPPA) data compares protein expression in OVCAR3 ovarian cancer cells treated with DMSO, DT2216, paclitaxel, or a combination. The dataset contains linear (L4) data from an analysis performed by the M.D. Anderson Functional Proteomics RPPA Core. It was authored by Kristopher Sarosiek and last updated on 2026-05-28.
Use Cases
- Compare protein expression profiles based on drug treatment conditions described in the experiment.
- Identify potential protein biomarkers of drug response based on RPPA analysis.
- Investigate synergistic or antagonistic effects of drug combinations on protein signaling pathways.
- Validate proteomic changes associated with paclitaxel or DT2216 treatment in a controlled cell line model.
Strengths
- Data was generated by the M.D. Anderson Functional Proteomics RPPA Core, a specialized facility.
- Experimental design includes vehicle control and single/combination drug treatments for comparison.
- The dataset uses linear (L4) data for protein expression comparison.
Limitations
- Column-level documentation is absent; field semantics must be inferred after download.
- Row count is unknown, which may limit suitability assessment.
- Description metadata is limited; actual data quality requires manual inspection after download.
Provenance
- Source
- M.D. Anderson Functional Proteomics RPPA Core
- Collection Method
- Cells were treated, harvested, and analyzed via Reverse Phase Protein Array (RPPA).
- Freshness
- Last updated 2026-05-28 22:37:24; freshness should be verified.